# CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study

> **NCT01719835** · PHASE2 · UNKNOWN · sponsor: **Royal Marsden NHS Foundation Trust** · enrollment: 87 (actual)

## Conditions studied

- Peripheral T-cell Lymphoma NOS
- Anaplastic Large Cell Lymphoma, ALK-Negative
- Angioimmunoblastic T-cell Lymphoma
- Hepatosplenic Gamma/ Delta T-cell Lymphoma
- Enteropathy-Associated T-Cell Lymphoma

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Gemcitabine
- **DRUG:** Doxorubicin
- **DRUG:** Vincristine
- **DRUG:** Prednisolone
- **DRUG:** methylprednisolone
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT01719835
- **Lead sponsor:** Royal Marsden NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-03
- **Primary completion:** 2016-11-30
- **Final completion:** 2022-08
- **Target enrollment:** 87 (ACTUAL)
- **Last updated:** 2018-03-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01719835

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01719835, "CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01719835. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*